Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors not recorded

N Engl J Med2015PMID 26287849PMC4971773stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (10)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 10

cancerCholangiocarcinomacivic_curation1.00
cancerLangerhans Cell Histiocytosiscivic_curation1.00
cancerLung Non-Small Cell Carcinomacivic_curation1.00
cancerMalignant Colorectal Neoplasmcivic_curation1.00
cancerThyroid Gland Anaplastic Carcinomacivic_curation1.00
drugCetuximabcivic_curation1.00
drugVemurafenibcivic_curation1.00
geneBRAFcivic_curation1.00
variantBRAF V600civic_curation1.00
variantBRAF V600Ecivic_curation1.00

Curated evidence

Evidence citing this paper (7)

civicCuratedShowing 1–7 of 7 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V6005
Vemurafenib	Cholangiocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID5905 Eight patients with BRAF V600 (7 with V600E, 1 with V600 unknown) mutated cholangiocarcinoma received vemurafenib. Only one patients showed partial response and duration of response of this patient wa… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic
〃	Langerhans Cell Histiocytosis	Predictive	B	Supports Sensitivity Response	3	accepted	EID1575 Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated. Of the 14 patients with Langerhans’-cell histiocytosis, 43% of patients had a respo… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID1574 Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated. Of the 20 patients with non-small-cell-lung cancer (17 with BRAF V600E, one with BRA… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic
Cetuximab + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID1598 Patients with BRAF-V600 mutated cancers were identified (n=122) and subsequently underwent targeted therapy. 27 patients with colorectal cancer were treated with vemurafenib and cetuximab (N=24 with B… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic
Vemurafenib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID1576 Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated. Of the 10 patients with colorectal cancer (80% BRAF V600E, 20% V600 unknown status)… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic
BRAF V600E2
Vemurafenib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID3742 In a clinical study of 122 cancer patients, including 37 previously treated colorectal cancer patients harboring BRAF V600 (V600E=32; V600 unknown=5) mutations, stable disease and progressive disease … (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic
〃	Thyroid Gland Anaplastic CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID6045 In a phase 2 “basket” study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete res… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic